In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer (2017)

Peer-Reviewed Study · Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; et al. · August 2017

Kodama M et al., 2017-08: In vivo shRNA and CRISPR screens in ovarian cancer xenografts identifying KPNB1 (importin beta-1) as a druggable oncogene, with ivermectin reproducing the KPNB1-dependent antitumour effect through cell cycle arrest and apoptosis.

Interestingly, ivermectin, a Food and Drug Administration-approved antiparasitic drug, showed KPNB1-dependent antitumor effects on EOC, serving as an alternative

n/a (HTML full text)

Kodama M et al., 2017-08: In vivo shRNA and CRISPR screens in ovarian cancer xenografts identifying KPNB1 (importin beta-1) as a druggable oncogene, with ivermectin reproducing the KPNB1-dependent antitumour effect through cell cycle arrest and apoptosis. Study type: in vivo shRNA/CRISPR dropout screens in human tumour xenografts + cell-line validation. N: not stated in the abstract. Country: USA (MD Anderson Cancer Center, Houston). Dose: not stated in the abstract. Funder: US government (NCI) support per publication type. Declared COI: 'The authors declare no conflict of interest.' Comparator: KPNB1 knockdown and control shRNA. Excerpt ends mid-sentence because the abstract sentence continues; the quoted words are continuous. Study type: animal.